THE TAPE

Oruka Therapeutics, Inc. Common Stock

$99.24▼ −5.80%
Last close
Relative strength
98RS
of 99, against every stock▲ +8 on the month
Powering up
Developing
+53.1%
six months against Pharmaceutical Preparations
52-week range
−14.1%
from the high
$25.23$115.52
Setup
On no screen
No base, flag or squeeze in place tonight. What is and is not there
2 days
Nov 18 · confirmed
No US GAAP filings to read.
Why it is on no screen

ORKA is off the screens on one check: shallow enough.

A base has formed12.6 weeks, from 70.50 to 115.52.
Long enough to count12.6 weeks against 3 needed.
Shallow enough39.0% deep against 35% allowed.
Close to its pivot-14.1% from the pivot; listed down to -20%.
Relative strengthRS 98 against 70 needed.

Measured against the base-and-breakout thresholds. The other screens use their own numbers, so a name can miss here and still be a fair-looking chart.

Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year
Support and resistance
Support below
$96.53
-2.7% · tested 10× · last 7 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

Oruka Therapeutics, Inc. Common Stock is not on any of the screens right now. Its relative strength rating is 98, and it sits in Pharmaceutical Preparations.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+32.1%
Three months against its industry
+1.4%
Six months against its industry
+53.1%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Peers
Catalyst roadmap
2
days
Earnings in 2 days
Nov 18, 2026
  1. Earningsconfirmedin 2d
    Quarterly earnings
    Nov 18, 2026
How it moves on earnings

On average 5.7% either way across its last 8 reports.

Checking your subscription…

Close before the report day to close after it, so it holds whether the company reported before the open or after the close.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 2 of 46 tracked funds at the end of Q3 2026.

Last quarter: 2 trimmed.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep
Unusual volumeTape · 2026-11-11
4.6 sigma
After this signal, stocks have lagged random stocks by 0.1% over the next three sessions (6,474 cases over 55 nights). Against their own sector they have lagged by 0.4%.
Closed above its 20- and 50-day on heavy volumeTape · 2026-11-10
above 20d & 50d on 1.7x volume at 104.56
Mixed: stocks have outrun random stocks by 0.2% over three sessions, not consistently enough to call (1,668 cases over 60 nights). Against their own sector they have lagged by 0.7%.
GappedTape · 2026-11-07
+7.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-11-06
-5.3%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
Tightening after a sharp runTape · 2026-11-04
range halved after a +35% thrust, at 99.55
No measurable effect: stocks behave like random ones over the next three sessions (887 cases over 60 nights).
Earnings date movedEvent · 2026-10-28
2026-11-10 -> 2026-11-18
No measurable effect: stocks behave like random ones over the next three sessions (2,989 cases over 51 nights).
GappedTape · 2026-10-28
+6.1%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.
GappedTape · 2026-10-27
+12.7%
After this signal, stocks have lagged random stocks by 0.9% over the next three sessions (18,291 cases over 56 nights). Against their own sector they have lagged by 1.2%.

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means. The track record is the sweep's own, measured against random stocks over the last 90 days.

In the news
Insiders
Bought on the open market
0
Sold on the open market
89
$336,559,815 total

Sold: Klein Lawrence Otto, Quinlan Paul T, Goncalves Joana, Agarwal Arjun, Sandler Laura Lee, Fairmount Funds Management LLC, Dambkowski Carl.

Not counted above: 29 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directoroption exercise25,000$195,000
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directorsell6,466$612,794
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directorsell15,036$1,437,987
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directorsell2,442$236,147
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directorsell756$73,676
2026-11-02 Klein Lawrence Otto · Chief Executive Officer, Directorsell300$29,521
2026-10-20 Quinlan Paul T · General Counseloption exercise9,000$70,200
2026-10-20 Quinlan Paul T · General Counselsell400$29,960

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What analysts expect
Strong buy2
Buy11
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray

No completed base to compare this one with yet.

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Oruka Therapeutics, Inc. Common Stock (ORKA) — The Tape